BT-205

**BT-205** is an investigational, sublingual fixed-dose analgesic combination developed by Bridge Therapeutics for moderate-to-severe chronic pain in opioid-experienced patients. It combines **buprenorphine**, a partial agonist at the mu-opioid receptor, with **meloxicam**, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes, including COX-2. Bridge Therapeutics identifies BT-205 as a patented combination covered by U.S. Patent 8410092 and has also referred to the product as Bucam. ([bridgetherapeutics.com](https://bridgetherapeutics.com/))

Brand names

Bucam

Other names

buprenorphine + meloxicambuprenorphine-meloxicam